**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 69959

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Study***

**Clustering cases of *Chlamydia psittaci* pneumonia mimicking COVID-19 pneumonia**

Zhao W *et al*. *Chlamydia psittaci* Pneumonia Mimicking COVID-19

Wei Zhao, Lei He, Xing-Zhi Xie, Xuan Liao, De-Jun Tong, Shang-Jie Wu, Jun Liu

**Wei Zhao, Xuan Liao, Jun Liu,** Department of Radiology, The Second Xiangya Hospital, Central South University, Changsha 410011, Hunan Province, China

**Wei Zhao, Jun Liu,** Clinical Research Center for Medical Imaging in Hunan Province, Changsha 410011, Hunan Province, China

**Lei He,** Department of Radiology, The First People’s Hospital of Yueyang, Yueyang 410005, Hunan Province, China

**Xing-Zhi Xie,** Department of Radiology, Hunan Chest Hospital, Changsha 410013, Hunan Province, China

**De-Jun Tong,** Hospital Infection Control Center, The Second Xiangya Hospital, Changsha 410011, Hunan Province, China

**Shang-Jie Wu,** Pulmonary and Critical Care Medicine, The Second Xiangya Hospital, Changsha 410011, Hunan Province, China

**Author contributions:** Zhao W, He L, Xie X, Liao X, Tong D, Wu S and Liu J designed and performed the research; Zhao W analyzed the data; Zhao W and Liu J wrote the manuscript; all authors provided input on the final version of the manuscript.

**Supported by** the National Natural Science Foundation of China, No. 82102157; Hunan Provincial Natural Science Foundation of China, No. 2021JJ40895; the Science and Technology Innovation Program of Hunan Province, No. 2020SK53423; and the Clinical Research Center For Medical Imaging in Hunan Province, No. 2020SK4001.

**Corresponding author: Jun Liu, MD, Professor,** Department of Radiology, The Second Xiangya Hospital, Central South University, No. 139 Middle Remin Road, Changsha 410011, Hunan Province, China. junliu123@csu.edu.cn

**Received:** July 18, 2021

**Revised:** October 11, 2021

**Accepted:** November 14, 2021

**Published online:** December 26, 2021

**Abstract**

BACKGROUND

The onset symptoms of people infected by *Chlamydia psittaci* can mimic the coronavirus disease 2019 (COVID-19). However, the differences in laboratory tests and imaging features between psittacosis and COVID-19 remain unknown.

AIM

To better understand the two diseases and then make an early diagnosis and treatment

METHODS

Six patients from two institutions confirmed as psittacosis by high-throughput genetic testing and 31 patients confirmed as COVID-19 were retrospectively included. The epidemiology, clinical characteristics, laboratory tests and computed tomography (CT) imaging features were collected and compared between the two groups. The follow-up CT imaging findings of patients with psittacosis were also investigated.

RESULTS

The white blood cell count (WBC), neutrophil count and calcium were more likely to be decreased in patients with COVID-19 but were increased in patients with psittacosis (all *P* = 0.000). Lymphocyte count and platelet count were higher in patients with psittacosis than in those with COVID-19 (*P* = 0.044, *P* = 0.035, respectively). Lesions in patients with psittacosis were more likely to be unilateral (*P* = 0.001), involve fewer lung lobes (*P* = 0.006) and have pleural effusions (*P* = 0.002). Vascular enlargement was more common in patients with COVID-19 (*P* = 0.003). Consolidation in lung CT images was absorbed in all 6 patients.

CONCLUSION

Psittacosis has the potential for human-to-human transmission. Patients with psittacosis present increased WBC count and neutrophil count and have specific CT imaging findings, including unilateral distribution, less involvement of lung lobes and pleural effusions, which might help us to differentiate it from COVID-19.

**Key Words:** *Chlamydia psittaci* pneumonnia; COVID-19; Computed tomography; Human-to-human transmission; Cluster

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Zhao W, He L, Xie XZ, Liao X, Tong DJ, Wu SJ, Liu J. Clustering cases of *Chlamydia psittaci* pneumonia mimicking COVID-19 pneumonia. *World J Clin Cases* 2021; 9(36): 11237-11247

**URL:** https://www.wjgnet.com/2307-8960/full/v9/i36/11237.htm

**DOI:** https://dx.doi.org/10.12998/wjcc.v9.i36.11237

**Core Tip:** In patients with coronavirus disease 2019 (COVID-19) the white blood cell count, neutrophil count and calcium were more likely to be decreased. Lymphocyte count and platelet count were higher in patients with psittacosis than those with COVID-19. Lesions in patients with psittacosis were more likely to be unilateral and involve less lung lobes and have pleural effusions.

**INTRODUCTION**

Since the new “unknown viral pneumonia” was detected in Wuhan, later named coronavirus disease 2019 (COVID-19), the outbreak of COVID-19 has rapidly spread to other cities in China and other countries and has posed a huge challenge to the global health system[1]. Many efforts have been made by medical staff worldwide to fight the disease. The situation of COVID-19 has been controlled in China; however, it is still serious in several countries, such as America and Brazil[2]. Considering the potential to import cases, Chinese people and the government are still enacting strict prevention and control measures, especially in hospitals.

The epidemiology, clinical characteristics, and imaging features have been substantially reported recently[3-6], which has helped us to better understand and fight the disease. Fever is one of the most common onset symptoms[5] but is nonspecific. Other infections caused by other viruses, bacteria, and fungi may also present fever in clinical practice, making it difficult to accurately screen out patients with COVID-19. Psittacosis, a zoonotic infectious disease caused by the bacterium *Chlamydia psittaci* (*C. psittaci*), is rarely diagnosed in the clinic. Humans can become infected through inhalation of aerosolized bacteria when exposed to infected birds or handling contaminated feathers, fecal material or carcasses[7,8]. The onset symptoms of people infected by *C. psittaci* include fever, chills, headache, malaise, myalgia, nonproductive coughing and dyspnea[9], which can mimic COVID-19. However, the differences in laboratory tests and imaging features between psittacosis and COVID-19 remain unknown.

Here, we report two clusters of cases with *C. psittaci* infection mimicking COVID-19 with the aims of better understanding the two diseases, making an early diagnosis and providing treatment. We hope this experience may contribute to fighting the COVID-19 outbreak.

**MATERIALS AND METHODS**

This retrospective study was approved by our Medical Ethical Committee (Approved No. 2020024), which waived the requirement for patients’ informed consent.

***Patients with C. psittaci pneumonia***

Four medical staff members who were working in the emergency rescue area or viewing area in the Second Xiangya Hospital (Cluster 1) and two slaughterhouse staff members treated in the First People’s Hospital of Yueyang (Cluster 2), who were confirmed to have *C. psittaci* pneumonia, were included in the current study. All of the patients presented onset symptoms of fever and underwent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing using real-time reverse transcription-polymerase chain reaction (RT-PCR). The IgG and IgM of COVID-19 were also tested. Moreover, the bronchoalveolar lavage fluid (BALF) of four patients was collected to identify suspicious pathogenic microorganisms (PMseq-DNA+RNA respiratory system infection pathogenic microbes high-throughput genetic testing: DNA testing, BGI), including 6350 species of bacteria with known sequences (including 174 species of mycobacteria and 137 species of mycoplasma/chlamydia/rickettsia), 1798 DNA viruses, 1064 fungi and 234 parasites. The number of detected sequences of *C. psittaci* was also recorded for each patient. The epidemiology, clinical characteristics, and laboratory tests (upon first admission) were also collected. In Cluster 1, one of the four patients had taken medicine before high-throughput genetic testing. Moreover, another patient who presented the same symptoms was identified as suspected patient 0 (patient 0 in Cluster 1). However, this patient only underwent RT-PCR testing for COVID-19 and was not confirmed to have *C. psittaci* by high-throughput genetic testing. In Cluster 2, one patient confirmed with *C. psittaci* by high-throughput genetic testing was identified as suspected patient0 (patient 0 in Cluster 2). However, the patient was admitted to another hospital, and the medical history was unavailable.

***Patients with COVID-19***

Confirmed COVID-19 patients from January 23, 2020 to February 10, 2020 in the Second Xiangya Hospital were also collected and compared with patients with *C. psittaci*. The diagnosis of COVID-19 was determined according to at least two positive results by real-time reverse-transcription-polymerase chain reaction (RT-PCR) assay for COVID-19. The epidemiology, clinical characteristics, computed tomography (CT) images, and laboratory tests were collected.

***Imaging interpretation***

Four patients underwent two CT scans with the Somatom go Now scanner (Siemens Medical, Shanghai, China). The CT images were reviewed blindly and independently by two radiologists (with 5 and 15 years of experience) in consensus. The detailed imaging interpretations were described in our previous studies[6,10].

***Statistical analysis***

Continuous variables were compared with the Mann-Whitney U test and are presented as the medians (IQR). Categorical variables are presented as the numbers (%) and were compared by Fisher’s exact test between the psittacosis and COVID-19 groups. A two-sided *P* value of less than 0.05 was considered statistically significant. All statistical analyses were performed using SPSS software (version 24.0).

**RESULTS**

***The relationship and chronology of symptom onset of the 4 patients with psittacosis***

All of the included patients had an onset symptom of fever, and the relationship and chronology of symptom onset in the two clusters are described in Figure 1. In Cluster 1, potential patient 0, who had an exposure history to poultry, visited his son on May 20, 2020. The last time they had been together was May Day. On May 27, 2020, they all developed fever symptoms and went to the fever clinic for COVID-19 screening. On the same day, they underwent chest CT scanning. From May 20 to May 27, Patient 1 worked in our hospital as usual and had direct contact with Patient 2, Patient 3, and Patient 4. Patients 2-4 successively developed fever. All five patients were identified as SARS-CoV-2 negative (all confirmed by RT-PCR and IgG, IgM testing), and the BALF of Patients 1-4 was collected for high-throughput genetic testing; all were identified as *C. psittaci*-positive. Note that patient 2 had taken medicine before high-throughput genetic testing. In Cluster 2, all patients were slaughterhouse staff and had a direct exposure history to poultry. The potential Patient 0 first developed fever, and Patients1 and Patients2 subsequently developed similar symptoms on April 24 and 27. All three patients were identified as *C. psittaci*-positive by high-throughput genetic testing.

***The clinical characteristics and laboratory tests of patients with COVID-19 and C. psittaci pneumonia***

From January 23, 2020 to February 10, 2020, 31 patients were confirmed to be COVID-19-positive in our hospital. The clinical characteristics and laboratory tests of patients with COVID-19 and psittacosis are described and compared with those of patients with *C. psittaci* in Table 1. Due to the uncertain diagnosis for patient 0, we only analyzed the clinical factors of patients 1-4 in Cluster 1 and patients1-2 in Cluster 2. Therefore, the clinical information of patient 01 was only considered as a reference. In terms of age, there were no significant differences between the two groups. The greatest differences between the two groups were the WBC count and neutrophil count (*P* = 0.000), which presented an opposite change trend. The white blood cell count and neutrophil count were more likely to be decreased in patients with COVID-19 but were increased in patients with psittacosis. Lymphocyte count and platelet count were higher in patients with psittacosisthan in those with COVID-19 (*P* = 0.044, *P* = 0.035, respectively). C-reactive protein (CRP) was increased in both groups and was more remarkable in patients with psittacosis (*P* = 0.035). Calcium was higher in patients with COVID-19 than in those with psittacosis (*P* = 0.000).

***The imaging findings of patients with COVID-19 and******psittacosis***

All six confirmed patients underwent CT scanning, and 15 of 31 patients with COVID-19 underwent CT scanning. The imaging findings of the patients in the two groups are presented and compared in Table 2. Note that 2 of 15 patients with COVID-19 presented normal CT findings. Lesions in patients with psittacosiswere more likely to be unilateral (*P* = 0.001) and involve fewer lung lobes (*P* = 0.006) than those infected by COVID-19 (Figures 2, 3 and 4). Vascular enlargement was more common in patients with COVID-19 (*P* = 0.003) (Figure 4), whereas pleural effusions were more common in patients with psittacosi*s* (*P* = 0.002). Although there was no significant difference regarding the predominant lesion type between the two groups, pure ground-glass opacity was not seen in patients with psittacosis. All of the lesions in patients with psittacosis were located in lower lung lobes. The transverse distribution, air bronchogram, margin and reticulation were not significantly different between the two groups. Note that the imaging findings of patient 0 were similar to those of patients 1-4 (Figure 3). Moreover, patients 0 and 1 presented a larger lesion area than patients 2-4.

***The treatment of patients with psittacosis and their follow-up CT image findings***

All patients with psittacosis were treated with piperacillin and moxifloxacin, and the symptoms were relieved. Consolidation in lung CT images was absorbed in all 6 patients; however, patients 2-4 had an increased involvement area and presented with ground-glass opacity (GGO) (Figures 2 and 3). Other people who had close contact with patients 1-4 excluded *C. psittaci* infection based on clinical symptoms. No further similar cases were found in any of the staff in the screening ward and their family members, nor did nosocomial infection related to the six cases occur.

**DISCUSSION**

In this study, we report a cluster of 4 cases (medical staff) confirmed with psittacosis. The clinical characteristics, laboratory tests and CT imaging findings were investigated and compared with patients confirmed to have COVID-19. Patients with psittacosis were more likely to present increased WBC count and neutrophil count and have specific CT imaging findings, including unilateral distribution and less involvement of lung lobes and pleural effusions.

The outbreak of COVID-19 is still ongoing around the world and threatens global public health. Although recent studies have made progress on vaccines for SARS-CoV-2[11,12], early diagnosis, which could prevent the spread of the virus, avoid cross-infection and promote early treatments, remains the best strategy to fight the disease. Fever, clustering outbreaks and pneumonia all favor potential infection by SARS-CoV-2. However, infections caused by other pathogenic factors also need attention. Psittacosis is a sporadic disease in clinical practice, with a rare incidence of human-to-human transmission[13,14]. The symptoms of psittacosis are nonspecific[15], but fever is usually the onset symptom[16], which can mimic COVID-19. In our study, four medical staff members who presented the onset symptom of fever were successively diagnosed with psittacosis by high-throughput genetic testing, indicating potential human-to-human transmission. All 4 confirmed patients with psittacosis were young (aged 26-48), which is consistent with a previous study[17]. However, COVID-19 has not shown an age preference[3].

The laboratory tests of patients with psittacosis also have clinically important differences regarding the WBC count and lymphocyte count compared with patients with COVID-19. Decreased WBC count and lymphocyte count are considered specific clinical presentations of COVID-19[18,19]. However, the two laboratory indices were both increased in all 6 patients. Moreover, the neutrophil count and platelet count were higher in patients with psittacosis than in patients with COVID-19 (*P* = 0.000, *P* = 0.035). The abovementioned differences may be attributed to the different reactions against viral and bacterial infections. Viral infection may generate a series of immune responses and cause changes in peripheral WBCs and immune cells, such as lymphocytes[19]. In contrast, bacterial infection usually causes an increased WBC count[20,21]. A higher level of CRP is more often seen in bacterial infections than in viral infections[22], which was also observed in our study (*P* = 0.035). Another interesting result is that calcium was lower in patients with COVID-19 than in those with psittacosis, which is supported by previous studies[23,24].

CT plays an important role in screening, diagnosing and evaluating the treatment response of COVID-19. It also has the advantage of differentiating COVID-19 pneumonia from other viral-infected pneumonias[25]. In the current study, several imaging features could differentiate COVID-19 pneumonia from psittacosis. Specifically, lesions in patients with psittacosis were more likely to be unilateral (*P* = 0.001), involve fewer lung lobes (*P* = 0.006) and present pleural effusions (*P* = 0.002). These aforementioned imaging features are uncommon in patients with COVID-19[6,26]. The follow-up CT changes of patients with psittacosis are also reported in the current study. Our results showed that the consolidations on CT images were absorbed after the treatment but with an increased involvement area, and GGOs were present in 3 patients. However, the follow-up CT imaging features are different in patients with COVID-19, which mostly present GGO lesions on the initial CT images and then change into consolidations on subsequent CT scans[27].

The clinical factors, laboratory tests and imaging features of patients who had not been diagnosed with psittacosis (patient 0) were similar to those of patients 1-4. Moreover, patient 0 had an exposure history to poultry. Therefore, there is reason to suspect that Patient 0 might be patient 0 in Cluster 1 and have transmitted the virus to patients 1-4. Other evidence of potential human-to-human transmission was obtained in Cluster 2. Patient0 developed fever first and transmitted the virus to his neighbors (Patients1 and Patients2 ). Of course, there is no robust evidence to directly support the view of human-to-human transmission. Further and deeper analyses should be performed.

The current study has several limitations. First, the included sample size was small, especially for patients with psittacosis. The statistical analyses between the two groups are only for reference. However, psittacosis is indeed a rarely diagnosed disease. Only 72 human cases were diagnosed and reported to the Centers for Disease Control and Prevention (CDC) in the United States during 2005-2012[28]. Clustering outbreaks of psittacosis are rare in clinical practice. Second, we only included two successive CT scans for patients with psittacosis. The CT changes over the entire course of treatment were not investigated.

**CONCLUSION**

Psittacosis has the potential for human-to-human transmission. Patients with psittacosis present increased WBC count and neutrophil count and have specific CT imaging findings, including unilateral distribution, less involvement of lung lobes and pleural effusions, which might help us to differentiate it from COVID-19 in clinical practice.

**ARTICLE HIGHLIGHTS**

***Research background***

Psittacosis, a zoonotic infectious disease caused by the bacterium Chlamydia (*C.*) psittaci, is rarely diagnosed in clinical and can mimic the coronavirus disease 2019 (COVID-19). However, the differences in laboratory tests and imaging features between psittacosis and COVID-19 remain unknown.

***Research motivation***

We want to share the experiences of two clusters of cases with *C. psittaci* infection and hope the experience may contribute a little to fight the outbreak of COVID-19.

***Research objectives***

Here we report two clusters of cases with *C. psittaci* infection which mimicking COVID-19 with the aim to better understand the two diseases and then make an early diagnosis and treatment.

***Research methods***

We reported a cluster of 4 cases (medical staffs) confirmed with psittacosis. The clinical characteristics, laboratory tests and CT imaging findings were comprehensively investigated and compared with patients confirmed as COVID-19.

***Research results***

The two diseases have different characteristics regarding lab tests and imaging features. In patients with COVID-19, the white blood cell count (WBC), neutrophil count and calcium were more likely to be decreased and have vascular enlargement. In patients with psittacosis. Lymphocyte count and platelet count were higher and lesions presented on CT images were more likely to be unilateral, involve fewer lung lobes and have pleural effusions.

***Research conclusions***

Psittacosis has the potential ability of human-to-human transmission. Patients with psittacosis present increased WBC count, neutrophil count and have specify CT imaging findings, including unilateral distribution, less involvement lung lobes and pleural effusions, which might help us to differentiate it from COVID-19 in clinical practice.

***Research perspectives***

Firstly, including more samples to further investigate the two diseases and support the conclusion. Secondly, including more kinds of pneumonia caused by other viruses to better diagnose the COVID-19.

**REFERENCES**

1 **Wang C**, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. *Lancet* 2020; **395**: 470-473 [PMID: 31986257 DOI: 10.1016/S0140-6736(20)30185-9]

2 **World Health Organization website**. WHO Coronavirus (COVID-19) Dashboard. [cited 15 July 2021]. Available from: https://covid19.who.int/

3 **Guan WJ**, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* 2020; **382**: 1708-1720 [PMID: 32109013 DOI: 10.1056/NEJMoa2002032]

4 **Yang X**, Yu Y, Xu J, Shu H, Xia J, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu T, Wang Y, Pan S, Zou X, Yuan S, Shang Y. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med* 2020; **8**: 475-481 [PMID: 32105632 DOI: 10.1016/S2213-2600(20)30079-5]

5 **Huang C**, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020; **395**: 497-506 [PMID: 31986264 DOI: 10.1016/S0140-6736(20)30183-5]

6 **Zhao W**, Zhong Z, Xie X, Yu Q, Liu J. Relation Between Chest CT Findings and Clinical Conditions of Coronavirus Disease (COVID-19) Pneumonia: A Multicenter Study. *AJR Am J Roentgenol* 2020; **214**: 1072-1077 [PMID: 32125873 DOI: 10.2214/AJR.20.22976]

7 **West A**. A Brief Review of Chlamydophila psittaci in Birds and Humans. *J Exot Pet Med* 2011; **1**: 18-20 [DOI: 10.1053/j.jepm.2010.11.006]

8 **Hogerwerf L**, DE Gier B, Baan B, VAN DER Hoek W. *Chlamydia psittaci* (psittacosis) as a cause of community-acquired pneumonia: a systematic review and meta-analysis. *Epidemiol Infect* 2017; **145**: 3096-3105 [PMID: 28946931 DOI: 10.1017/S0950268817002060]

9 **Rybarczyk J**, Versteele C, Lernout T, Vanrompay D. Human psittacosis: a review with emphasis on surveillance in Belgium. *Acta Clin Belg* 2020; **75**: 42-48 [PMID: 30882289 DOI: 10.1080/17843286.2019.1590889]

10 **Zhao W**, Zhong Z, Xie X, Yu Q, Liu J. CT Scans of Patients with 2019 Novel Coronavirus (COVID-19) Pneumonia. *Theranostics* 2020; **10**: 4606-4613 [PMID: 32292517 DOI: 10.7150/thno.45016]

11 **Wang H**, Zhang Y, Huang B, Deng W, Quan Y, Wang W, Xu W, Zhao Y, Li N, Zhang J, Liang H, Bao L, Xu Y, Ding L, Zhou W, Gao H, Liu J, Niu P, Zhao L, Zhen W, Fu H, Yu S, Zhang Z, Xu G, Li C, Lou Z, Xu M, Qin C, Wu G, Gao GF, Tan W, Yang X. Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2. *Cell* 2020; **182**: 713-721.e9 [PMID: 32778225 DOI: 10.1016/j.cell.2020.06.008]

12 **Gao Q**, Bao L, Mao H, Wang L, Xu K, Yang M, Li Y, Zhu L, Wang N, Lv Z, Gao H, Ge X, Kan B, Hu Y, Liu J, Cai F, Jiang D, Yin Y, Qin C, Li J, Gong X, Lou X, Shi W, Wu D, Zhang H, Zhu L, Deng W, Li Y, Lu J, Li C, Wang X, Yin W, Zhang Y, Qin C. Development of an inactivated vaccine candidate for SARS-CoV-2. *Science* 2020; **369**: 77-81 [PMID: 32376603 DOI: 10.1126/science.abc1932]

13 **Wallensten A**, Fredlund H, Runehagen A. Multiple human-to-human transmission from a severe case of psittacosis, Sweden, January-February 2013. *Euro Surveill* 2014; **19** [PMID: 25358043 DOI: 10.2807/1560-7917.es2014.19.42.20937]

14 **Ito I**, Ishida T, Mishima M, Osawa M, Arita M, Hashimoto T, Kishimoto T. Familial cases of psittacosis: possible person-to-person transmission. *Intern Med* 2002; **41**: 580-583 [PMID: 12132529 DOI: 10.2169/internalmedicine.41.580]

15 **Balsamo G**, Maxted AM, Midla JW, Murphy JM, Wohrle R, Edling TM, Fish PH, Flammer K, Hyde D, Kutty PK, Kobayashi M, Helm B, Oiulfstad B, Ritchie BW, Stobierski MG, Ehnert K, Tully TN Jr. Compendium of Measures to Control *Chlamydia psittaci* Infection Among Humans (Psittacosis) and Pet Birds (Avian Chlamydiosis), 2017. *J Avian Med Surg* 2017; **31**: 262-282 [PMID: 28891690 DOI: 10.1647/217-265]

16 **Knittler MR**, Sachse K. *Chlamydia psittaci*: update on an underestimated zoonotic agent. *Pathog Dis* 2015; **73**: 1-15 [PMID: 25853998 DOI: 10.1093/femspd/ftu007]

17 **Shaw KA**, Szablewski CM, Kellner S, Kornegay L, Bair P, Brennan S, Kunkes A, Davis M, McGovern OL, Winchell J, Kobayashi M, Burton N, de Perio MA, Gabel J, Drenzek C, Murphy J, Holsinger C, Forlano L. Psittacosis Outbreak among Workers at Chicken Slaughter Plants, Virginia and Georgia, USA, 2018. *Emerg Infect Dis* 2019; **25**: 2143-2145 [PMID: 31625859 DOI: 10.3201/eid2511.190703]

18 **COMMISSION**. Diagnosis and treatment of pneumonitis caused by new coronavirus (trial version 7). Beijing: China National Health Commission, 2020. [cited 12 June 2020]. Available from: http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml

19 **Chen N**, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* 2020; **395**: 507-513 [PMID: 32007143 DOI: 10.1016/S0140-6736(20)30211-7]

20 **Bhuiyan MU**, Blyth CC, West R, Lang J, Rahman T, Granland C, de Gier C, Borland ML, Thornton RB, Kirkham LS, Martin A, Richmond PC, Smith DW, Jaffe A, Snelling TL. Combination of clinical symptoms and blood biomarkers can improve discrimination between bacterial or viral community-acquired pneumonia in children. *BMC Pulm Med* 2019; **19**: 71 [PMID: 30940126 DOI: 10.1186/s12890-019-0835-5]

21 **Karakonstantis S**, Kalemaki D. Correspondence to "Role of neutrophil to lymphocyte and monocyte to lymphocyte ratios in the diagnosis of bacterial infection in patients with fever". *Infection* 2018; **46**: 139-140 [PMID: 28887604 DOI: 10.1007/s15010-016-0972-1]

22 **Don M**, Valent F, Korppi M, Canciani M. Differentiation of bacterial and viral community-acquired pneumonia in children. *Pediatr Int* 2009; **51**: 91-96 [PMID: 19371285 DOI: 10.1136/thorax.57.5.438]

23 **Lippi G**, South AM, Henry BM. Electrolyte imbalances in patients with severe coronavirus disease 2019 (COVID-19). *Ann Clin Biochem* 2020; **57**: 262-265 [PMID: 32266828 DOI: 10.1177/0004563220922255]

24 **Cappellini F**, Brivio R, Casati M, Cavallero A, Contro E, Brambilla P. Low levels of total and ionized calcium in blood of COVID-19 patients. *Clin Chem Lab Med* 2020; **58**: e171-e173 [PMID: 32459190 DOI: 10.1515/cclm-2020-0611]

25 **Bai HX**, Hsieh B, Xiong Z, Halsey K, Choi JW, Tran TML, Pan I, Shi LB, Wang DC, Mei J, Jiang XL, Zeng QH, Egglin TK, Hu PF, Agarwal S, Xie FF, Li S, Healey T, Atalay MK, Liao WH. Performance of Radiologists in Differentiating COVID-19 from Non-COVID-19 Viral Pneumonia at Chest CT. *Radiology* 2020; **296**: E46-E54 [PMID: 32155105 DOI: 10.1148/radiol.2020200823]

26 **Song F**, Shi N, Shan F, Zhang Z, Shen J, Lu H, Ling Y, Jiang Y, Shi Y. Emerging 2019 Novel Coronavirus (2019-nCoV) Pneumonia. *Radiology* 2020; **295**: 210-217 [PMID: 32027573 DOI: 10.1148/radiol.2020200274]

27 **Pan F**, Ye T, Sun P, Gui S, Liang B, Li L, Zheng D, Wang J, Hesketh RL, Yang L, Zheng C. Time Course of Lung Changes at Chest CT during Recovery from Coronavirus Disease 2019 (COVID-19). *Radiology* 2020; **295**: 715-721 [PMID: 32053470 DOI: 10.1148/radiol.2020200370]

28 **Adams DA**, Jajosky RA, Ajani U, Kriseman J, Sharp P, Onwen DH, Schley AW, Anderson WJ, Grigoryan A, Aranas AE, Wodajo MS, Abellera JP; Centers for Disease Control and Prevention (CDC). Summary of notifiable diseases--United States, 2012. *MMWR Morb Mortal Wkly Rep* 2014; **61**: 1-121 [PMID: 25233134]

**Footnotes**

**Institutional review board statement:** This retrospective study was approved by our Medical Ethical Committee (Approved No. 2020024), which waived the requirement for patients’ informed consent.

**Conflict-of-interest statement:** The authors declare that they have no conflict of interest.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** July 18, 2021

**First decision:** October 11, 2021

**Article in press:** November 14, 2021

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): 0

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Lozada-Martinez I **S-Editor:** Wang LL **L-Editor:** A **P-Editor:** Wang LL


**Figure Legends**



**Figure 1 The relationship and chronology of symptom onset of the 5 patients with psittacosis.**



**Figure 2 The imaging findings of 4 confirmed patients with psittacosis in cluster 1.** The predominant lesions type of 4 patients are consolidation or mixed ground-glass opacity (GGO) and consolidation (black thick arrow). Air bronchogram is presented in all patients. On follow-up computed tomography scans, the consolidations are absorbed and the area of GGO is extended in patients 2-4 (thin white arrow). The area of lesions is reduced in patient 1 (short white arrow).

****

**Figure 3 The computed tomography image finding of patients1-2 in cluster 2.** The patients1-2 have similar imaging findings (mixed ground-glass opacity and consolidation) to patients 1-4 and the lesions are absorbed on follow-up computed tomography.



**Figure 4 The computed tomography image finding of patient 0 and a case of coronavirus disease 2019.** The patient 0 have similar imaging findings (mixed ground-glass opacity and consolidation) to patients 1-4 (black thick arrow). The patients of coronavirus disease 2019 (COVID-19) presented multifocal and bilateral ground-glass opacity (white thin arrow) and vascular enlargement (white thick arrow). The margin of lesions in patients with COVID-19 is clearer. COVID-19: Coronavirus disease 2019.

**Table 1 The clinical characteristics and laboratory tests of patients with coronavirus disease 2019 and psittacosis**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Patient 0** | **Patient 1** | **Patient 2** | **Patient 3** | **Patient 4** | **Patient**1 | **Patient**2 | **Psittacosis (*n* = 6)** | **COVID-19 (*n* = 31)** | ***P* value** |
| Age | 62 | 36 | 29 | 32 | 26 | 47 | 48 | 34.00 (28.25-47.25) | 50.00 (32.00-66.00) | 0.073 |
| Sex | Male | Male | Female | Female | Male | Male | Male | NA | NA | 0.660 |
| Male |  |  |  |  |  |  |  | 4 | 16 |  |
| Female |  |  |  |  |  |  |  | 2 | 15 |  |
| Hemoglobin (g/dL); (male normal range 130-175; female normal range 115-150) | 124 | 142 | 135 | 134 | 163 | 157 | 143 | 142.50 (134.75-158.50)a | 135.00 (120.00-141.00) | 0.054 |
| White blood cell count (× 109/L); (normal range 3.5-9.5) | 7.14 | 10.43 | 10.07 | 11.7 | 10.53 | 10.26 | 14.36 | 10.48 (10.21-12.37) | 4.62 (3.31-6.17) | 0.000 |
| Neutrophil count (× 109/L); (normal range 1.8-6.3) | 5.92 | 7.57 | 6.61 | 8.66 | 8.41 | 6.3 | 11.76 | 7.99 (6.53-9.44) | 2.89 (1.95-3.89) | 0.000 |
| Lymphocyte count (× 109/L); (normal range 1.1-3.2) | 0.66 | 2.04 | 2.33 | 2.21 | 1.11 | 1.28 | 1.43 | 1.74 (1.24-2.24) | 1.09 (0.71-1.67) | 0.044 |
| Platelet count (× 109/L); (normal range 125-350) | 186 | 369 | 249 | 241 | 193 | 214 | 204 | 227 (201-279) | 183 (124-227) | 0.035 |
| Eosinophilic count (× 109/L); (normal range 0.02-o.52) | 0 | 0.1 | 0.01 | 0 | 0 | 0 | 0 | 0.000 (0.000-0.325) | 0.100 (0.000-0.400) | 0.265 |
| C-reactive protein (mg/L); (normal range 0.0-5.0) | 127.17 | 12.17 | 31.87 | 50.55 | 58.01 | 112.13 | 141.35 | 54.28 (26.95-119.44) | 15.60 (4.77-47.73) | 0.035 |
| Sodium (mmol/liter) | NA | 140.9 | 1136.2 | 134.2 | 136.1 | 129.7 | 137.4 | 136.15 (133.08-138.28) | 135.90 (133.40-137.40) | 0.857 |
| Potassium (mmol/liter) | NA | 4.09 | 3.42 | 3.42 | 3.94 | 4.11 | 3.52 | 3.73 (3.42-4.10) | 4.02 (3.58-4.37) | 0.302 |
| Calcium (mmol/liter) | NA | 2.11 | 2.28 | 2.03 | 2 | 2.2 | 2.16 | 2.14 (2.02-2.22) | 1.20 (1.18-1.22) | 0.000 |
| The number of detected sequences of *C. psittaci* | NA | 274 | 3 | 82 | 254 | NA | NA | NA | NA | NA |

aThe data presented are the medians (IQR). COVID-19: Coronavirus disease 2019; NA: Not applicable.

**Table 2 The imaging findings of patients with coronavirus disease 2019 and psittacosis**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Psittacosis (*n* = 6)** | **COVID-19 (*n* = 13)** | ***P* value** |
| Predominant lesion type |  |  | 0.221 |
| GGO | 0 (0) | 5 (38.5) |  |
| Consolidation | 3 (50) | 5 (38.5) |  |
| Mixed GGO and consolidation | 3 (50) | 3 (23.1) |  |
| Air bronchogram | 6 (100) | 8 (61.5) | 0.128 |
| Vascular enlargement | 1 (16.7) | 12 (92.3) | 0.003 |
| Margin (uneasily differentiated) | 6 (100) | 8 (61.5) | 0.128 |
| Reticulation | 5 (75) | 9 (69.2) | 1.000 |
| Pleural effusions | 6 (100) | 1 (7.7) | 0.002 |
| Craniocaudal distribution |  |  | 0.026 |
| Upper lung predominant | 0 (0) | 2 (15.4) |  |
| Lower lung predominant | 6 (100) | 4 (30.8) |  |
| No craniocaudal distribution | 0 (0) | 7 (53.8) |  |
| Transverse distribution |  |  | 0.255 |
| Central | 0 (0) | 0 (0) |  |
| Peripheral | 6 (100) | 9 (69.2) |  |
| No transverse distribution | 0 (0) | 4 (30.8) |  |
| Lung region distribution |  |  | 0.001 |
| Unilateral | 6 (100) | 2 (15.4) |  |
| Bilateral | 0 (0) | 11 (84.6) |  |
| Number of involved lung lobes |  |  | 0.006 |
| 1 | 6 (100) | 2 (15.4) |  |
| 2 | 0 (0) | 3 (23.1) |  |
| 3 | 0 (0) | 0 (0) |  |
| 4 | 0 (0) | 5 (38.5) |  |
| 5 | 0 (0) | 5 (38.5) |  |

Note: The data are presented as the numbers (percentages). GGO: Ground-glass opacity.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**